Notice of Intent to Sole Source – Miltenyi Biotec, Inc
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
The National Institutes of Health is issuing a notice of intent to sole source a Miltenyi Biotec GentleMACS Octo Dissociator with Heater for use in the Clinical Pharmacology Laboratory at its Bethesda, Maryland campus. This equipment is critical for the automated dissociation and homogenization of tissue samples from preclinical and clinical studies, enabling precise quantification of therapeutic agents and their metabolites via liquid chromatography-mass spectrometry for pharmacokinetic and tissue distribution analyses. The instrument supports essential translational research activities including biomarker discovery and pharmacokinetic/pharmacodynamic profiling across multiple NIH-sponsored protocols. The acquisition will be conducted under simplified acquisition procedures per FAR Part 13, Subpart 13.106-1(b)(1), as the contracting officer has determined that Miltenyi Biotec, Inc. is the only reasonable source due to the unique specifications and proprietary nature of the equipment, thereby exempting this procurement from full competition requirements. Comments regarding this intent must be submitted by the specified closing date to Ryssa Nix, Contract Specialist, at ryssa.nix@nih.gov, referencing solicitation number NOI-OD-26-006986.
General Info
Agency
NAICS
Place of Performance
Bethesda, MD, 20892, USASet-Aside
Timeline
Organization & Contact Information
Full Description
This is a notice of intent, not a request for a quotation. A solicitation document will not be issued and quotations will not be requested.
This procurement is for a Miltenyi Biotec GentleMACS Octo Dissociator with Heater to be located in the Clinical Pharmacology Laboratory (CPL) at the National Institutes of Health (NIH). The instrument is essential for the automated dissociation and homogenization of preclinical and clinical tissue samples prior to liquid chromatography-mass spectrometry (LC-MS) analysis. These procedures are required for the accurate quantification of therapeutic agents and their metabolites in tissues for pharmacokinetic (PK) and tissue distribution studies.This equipment is integral to the CPL’s role in supporting translational pharmacology, biomarker discovery, and pharmacokinetic/pharmacodynamic (PK/PD) profiling across multiple NIH protocols and collaborations.
This acquisition is being conducted using policies unique to the Federal Acquisition Regulation (FAR) Part 13 –Simplified Acquisition Procedures, Subpart 13.106-1(b)(1), For purchases not exceeding the simplified acquisition threshold (SAT), contracting officers may solicit from one source if the contracting officer determines that the circumstance of the contract action deem only one source reasonably available. Contracts awarded using FAR Part 13-Simplified Acquisition Procedures are exempt from the requirements of FAR Part 6-Competition Requirements.
Comments to this announcement, referencing this posting number, may be submitted to the NIH, Clinical Center, Office of Purchasing and Contracts, prior to the closing date specified in this announcement, to the attention of Ryssa Nix, Contract Specialist via email to Ryssa.nix@nih.gov by close date.
Similar Contracts
Same NAICS industry code
More opportunities from Department Of Health And Human Services → National Institutes Of Health Olao
Same awarding agency
Ready to Pursue This Opportunity?
Get AI-powered intelligence on this solicitation and the ones like it
Every page of the solicitation package shredded into a compliance breakdown
AI-powered matching based on your capabilities and past performance
Competitor and incumbent history on the requirement
Automated alerts on amendments, Q&A deadlines, and award
Join 650+ contractors already using CLEATUS
